In vitro studies have found creno to have superior cytotoxic effects compared to sorafenib (sora) or quizartinib and the compound is currently being evaluated in phase II trials in FLT3-ITD AML [14, 15]. The gene discussed is FLT3; the disease is acute myeloid leukemia.